Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DARK-Sepsis
NCT05824767Phase 4Completed
- Sponsor
- The University of New Mexico
- Start
- Apr 2023
- Primary completion
- Mar 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of Angiotensin II in septic shock, vasodilatory shock, sponsored by The University of New Mexico. Started Apr 2023; status: completed.
02
Drugs
Angiotensin II
03
Conditions
septic shockvasodilatory shock
Beyond the preview
Go deeper on NCT05824767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05824767.